Krystal Biotech Shares Surge on Expanded FDA Approval

Gene therapy specialist Krystal Biotech has achieved a significant regulatory milestone that is driving substantial investor interest. The company’s flagship treatment, VYJUVEK, has received a broadened approval from the U.S. Food and Drug Administration that dramatically increases its commercial potential and simplifies its administration.

Expanded Label Unlocks Major Market Opportunity

The FDA’s updated approval represents a fundamental shift for VYJUVEK’s market positioning. Treatment can now begin immediately after birth, removing all previous age restrictions and substantially widening the eligible patient population. More significantly, the therapy can now be administered in home settings by patients and their caregivers rather than requiring clinical visits.

Another critical change eliminates the previous 24-hour waiting period for dressing changes, making the entire treatment process considerably more patient-friendly. These regulatory updates stem from positive real-world evidence and results from an open-label study, confirming the treatment’s safety and efficacy across a broader demographic spectrum. The changes are expected to significantly accelerate adoption rates.

Strong Financial Performance Underpins Growth

Krystal Biotech’s recent quarterly results demonstrate VYJUVEK’s robust commercial performance. The company reported impressive financial metrics, with earnings per share of $1.29 and revenues reaching $96.04 million, substantially exceeding market expectations. The gene therapy product achieved a remarkable 93% gross margin and currently serves as the company’s sole revenue generator.

The balance sheet remains strong with $820.8 million in cash and investments, providing ample financial flexibility to support ongoing expansion efforts and pipeline development.

Should investors sell immediately? Or is it worth buying Krystal Biotech?

Global Expansion Gains Momentum

Beyond its U.S. success, Krystal Biotech is making significant strides in international markets. The company has already secured regulatory approvals in both Europe and Japan, with specific launch timelines established for key European markets. A German market introduction is scheduled for the third quarter of 2025, followed by a French launch in the fourth quarter of the same year.

Concurrently, the company is advancing its pipeline with KB707, an inhaled immunotherapy treatment targeting non-small cell lung cancer. An upcoming end-of-phase-2 meeting with the FDA will help clarify regulatory pathways for this promising oncology asset.

Analyst Sentiment Remains Largely Positive

Despite recent share price volatility, analytical coverage maintains a generally optimistic outlook. HC Wainwright reaffirmed its Buy recommendation with a $240 price target, while Chardan Capital maintains a $216 target. Even BofA Securities, which reduced its price objective to $182, sustained its Buy rating.

Company management has noted potential third-quarter revenue variability due to seasonal treatment pauses among patients. This pattern of new patient volatility represents an ongoing consideration within the specialized gene therapy market.

The expanded FDA approval provides Krystal Biotech with substantial commercial momentum. Whether this regulatory achievement will translate into a sustained reversal of the stock’s downward trend will depend on the successful commercial execution of these new opportunities.